AXON: Wall Street Is Dumping a Defense Gem
Key Takeaways
- Axon's revenue grew 32% in 2025 to $2.78 billion, with Q4 sequential growth accelerating to 12.1%.
- The 330x P/E is misleading — stock-based compensation crushes GAAP earnings while gross margins hold above 57.9%.
- Price-to-book has compressed from 23.6x to 14.1x, the cheapest valuation in over a year.
- Capital International's 22.6% stake reduction signals institutional capitulation, not fundamental deterioration.
- Defense technology spending is a secular tailwind with bipartisan political support.
Axon Enterprise has lost 44% of its value since peaking at $886 last year. At $491.85, the stock trades below its 200-day moving average of $661 and just saw Capital International Investors slash their position by 22.6%. The institutional exodus looks decisive.
But the selling tells you more about portfolio rebalancing than about Axon's business. Revenue grew 32% in 2025 — from $603.6 million in Q1 to $796.7 million in Q4 — while the company cements itself as the dominant platform for law enforcement technology. The 330x P/E ratio that scares off value screens is an artifact of stock-based compensation, not a broken business model. Strip out the noise, and Axon is a high-margin, high-growth defense tech compounder trading at its cheapest valuation in over a year.
Valuation: The P/E Mirage
At 330x trailing earnings, Axon looks absurd on a screener. But that multiple reflects just $1.49 in GAAP EPS — crushed by stock-based compensation that consumed the bulk of operating income. The more telling metric is price-to-book at 14.1x, which has compressed from 23.6x in June 2025.
EV/EBITDA tells a similar story of distortion: the trailing figure exceeds 800x because EBITDA was only $55.8 million in Q4 against a $39.5 billion market cap. But EBITDA is depressed by the same non-cash comp expense. Axon's gross margin held at 57.9-60.6% throughout 2025 — these are software-like margins on a hardware-plus-software platform.
The stock is down 44% from its $885.92 high while revenue grew 32%. That's the definition of multiple compression — not fundamental deterioration.
Earnings: Revenue Acceleration Hiding in Plain Sight
Axon delivered four consecutive quarters of revenue growth in 2025:
- Q1: $603.6 million
- Q2: $668.5 million (+10.8% QoQ)
- Q3: $710.6 million (+6.3% QoQ)
- Q4: $796.7 million (+12.1% QoQ)
That Q4 acceleration to 12.1% sequential growth is the number the market is ignoring. Full-year revenue hit approximately $2.78 billion, up from around $2.07 billion in the prior year.
Net income was volatile — $88 million in Q1 fell to a $2.2 million loss in Q3 before recovering to $3 million in Q4. The swing is almost entirely stock-based compensation timing, not operational weakness. Gross profit margins stayed above 57.9% every quarter.
Financial Health: Clean Balance Sheet, Growing Cash Flow
Axon's balance sheet is conservative for a growth company. The current ratio sits at 2.53, meaning short-term assets cover liabilities more than twice over. Debt-to-equity is just 0.59 — this is not a company leveraging up to fund growth.
Free cash flow per share reached $1.93 in Q4, rebounding from negative territory in Q2. The FCF trajectory is lumpy because of Axon's contract-based revenue model — large government deals create uneven cash collection cycles. But the direction is positive: Q4's $155 million in free cash flow (estimated from per-share figure times 80.4 million shares) represents real cash generation.
The 80.4 million shares outstanding have been relatively stable, though stock-based compensation continues to dilute at a pace that suppresses GAAP earnings. This is the trade-off: Axon retains top talent in a competitive defense tech market by paying in equity rather than cash.
Growth: The Law Enforcement Platform Play
Axon is not just a Taser company anymore. The business has evolved into an integrated platform: body cameras, cloud-based evidence management (Axon Evidence), records management, real-time operations, and AI-powered tools for law enforcement. Each product creates switching costs that lock in agencies for years.
The defense spending tailwind is real and bipartisan. Federal, state, and local law enforcement budgets are expanding across political lines. Axon's position as the dominant provider of body-worn cameras and digital evidence management gives it a near-monopoly in its core market.
Competition exists — Motorola Solutions in communications, various body camera startups — but no competitor offers the integrated platform that Axon has built. Agencies that adopt Axon's body cameras typically migrate to Evidence.com for storage, then layer on records management. The land-and-expand model is textbook SaaS applied to public safety.
Analyst estimates project revenue reaching $1.27 billion per quarter by Q1 2028 and $1.65 billion by Q4 2028 — roughly doubling from current levels.
Forward Outlook: Catalysts and Risks
Next earnings on May 6, 2026 will be the near-term catalyst. If Q1 2026 sustains the Q4 acceleration, the narrative shifts from "overvalued tech" to "underappreciated compounder."
Forward estimates are aggressive but grounded: analysts project EPS of $2.88 in Q1 2028 growing to $3.98 by Q4 2028. That implies significant margin expansion as stock-based compensation becomes a smaller percentage of revenue. At the current price of $491.85, the stock would trade at roughly 31x Q4 2028 annualized earnings — expensive, but reasonable for 30%+ revenue growth.
Risks are real. The stock-based compensation is not a rounding error — it dilutes shareholders and inflates the P/E. Government budget cycles create lumpiness. And at $39.5 billion market cap, Axon is priced for sustained execution with little margin for error.
The biggest risk is the one the market is pricing: what if revenue growth decelerates? At this valuation, a slowdown from 30% to 15% growth would crater the stock. That's the bear case — and it's why the stock is 44% off its highs.
Conclusion
The market is treating Axon like a momentum stock that lost its momentum. But the revenue growth never slowed — Q4's 12.1% sequential acceleration was the strongest quarter of 2025. What changed is the multiple investors were willing to pay, not the business trajectory.
Contrarians should be interested at $491.85. This is a high-margin, platform-dominant, defense-adjacent compounder trading at its lowest price-to-book in a year. The P/E is misleading, the balance sheet is clean, and the secular tailwind of law enforcement technology spending isn't going away. The institutional selling creates the opportunity — Capital International's 22.6% reduction puts shares in weaker hands at lower prices. For investors with a 2-3 year horizon who can stomach the stock-comp dilution, Axon below $500 is a gift from panicking momentum traders.
Frequently Asked Questions
Sources & References
financialmodelingprep.com
financialmodelingprep.com
financialmodelingprep.com
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.